TIDMRENX
Renalytix AI PLC
21 May 2019
Renalytix AI plc
("RenalytixAI" or the "Company")
RenalytixAI Expands Core Investigator Group
for Kidney Transplant Advanced Diagnostic Programme
Investigators now include transplant experts from University of
Oxford, Yale School of Medicine, Emory University School of
Medicine, Icahn School of Medicine at Mount Sinai, University of
Manitoba, Westmead Hospital Sydney, University of Alabama at
Birmingham, and Cleveland Clinic
Renalytix AI plc (AIM: RENX), a developer of artificial
intelligence-enabled clinical diagnostics for kidney disease,
announces the expansion of the core investigator group supporting
clinical and regulatory pathways for FractalDx, a portfolio of
advanced diagnostic and prognostic solutions in kidney
transplant.
As previously announced, RenalytixAI formed the FractalDx
investigator group as part of its commercial programme for advanced
diagnostic tests expected to make significant improvements in the
identification and monitoring for kidney transplant rejection, and
to aid in accurate dosing of immune-suppression therapy.
Kathryn Wood, DPhil, Professor of Immunology Emerita in the
Nuffield Department of Surgical Sciences at the University of
Oxford, said: "Predicting transplant rejection before damage to the
transplanted kidney occurs remains a major unmet need. Accurately
determining rejection risk for each transplant recipient allows
individualised treatment to be initiated before the transplanted
kidney is attacked and damaged by the immune system leading to
improved patient care and successful outcomes."
The number of kidney transplants steadily rises each year in the
United States and worldwide(1) with nearly 20 percent of
transplants failing within three years(2) . This highlights the
critical need for solutions that will address patient impact and
the growing cost of medical treatment associated with kidney
transplant complications.
Dr. Barbara Murphy, Dean for Clinical Integration and Population
Health, Professor and System Chair Medicine and Nephrology, at the
Icahn School of Medicine at Mount Sinai, and Chair of the
Scientific Advisory Board of RenalytixAI, said: "As the need for
kidney transplantation continues to increase due to the rapid
growth of the chronic kidney disease (CKD) epidemic, we must
determine a way to assess risk of organ rejection and personalise
treatment for each and every patient. Our expanded group of
investigators will help us in the ongoing development of prognostic
and diagnostic solutions to help address the crucial shortfalls
we're currently facing in the area of kidney transplantation."
The investigator appointments now include:
-- Richard Formica, MD - Professor of Medicine (Nephrology) and
Professor of Surgery (Transplant); Director of Transplant Medicine;
Director Outpatient Transplantation Service; Medical Director Adult
and Pediatric Kidney Transplantation; and Medical Director Pancreas
Transplantation at Yale School of Medicine
-- Christian P. Larsen, MD, DPhil - Professor of Surgery,
Division of Transplantation, Department of Surgery and the former
dean of the Emory University School of Medicine, and Founding
Director of the Emory Transplant Center
-- Roslyn B. Mannon, MD - Professor of Medicine in the Division
of Nephrology and Professor of Surgery in the Division of
Transplantation at the University of Alabama at Birmingham, and
Director of Research for the Comprehensive Transplant Institute
-- Barbara Murphy, MD - Dean for Clinical Integration and
Population Health, Professor and System Chair Medicine and
Nephrology, at the Icahn School of Medicine at Mount Sinai
-- Peter Nickerson, MD, FRCPC - Clinical Nephrologist, Professor
of Internal Medicine and Immunology, and Associate Dean for
Research at the University of Manitoba, and Executive Medical
Director, Organs and Tissue Office, at the Canadian Blood
Services
-- Philip O'Connell, MD - Clinical Professor in Medicine,
Director of the Centre for Transplant and Renal Research at the
Westmead Institute for Medical Research, and Director of Transplant
Medicine and the Clinical Islet Transplant Program at the Westmead
Hospital Sydney
-- Emilio D. Poggio, MD, FASN - Professor of Medicine at the
Cleveland Clinic Lerner College of Medicine of CWRU, and Medical
Director, Kidney and Kidney Pancreas Transplant Program, at the
Cleveland Clinic
-- Kathryn Wood, DPhil - Professor of Immunology Emerita in the
Nuffield Department of Surgical Sciences at the University of
Oxford
-- Weijia Zhang, PhD - Director, Integrative Bioinformatics and
Professor of Medicine, at the Icahn School of Medicine at Mount
Sinai
The FractalDx technology is based principally on sequencing
biomarkers from a patient's blood using widely available instrument
platforms. Products under development from the portfolio are
anticipated to be part of the extended RenalytixAI pipeline
following the introduction of KidneyIntelX in 2019 for the
diagnosis of fast-progressing chronic kidney disease.
As outlined in an announcement on 2 January, 2019, RenalytixAI
had exercised its option from the Icahn School of Medicine at Mount
Sinai ("ISMMS") for the exclusive license to technology and data
underlying the FractalDx product portfolio. The Company is expected
to initiate the clinical validation for the first diagnostic
product from the portfolio beginning in the second half of
2019.
Notes:
[1] United Network for Organ Sharing (UNOS), 2019
[2] National Kidney Foundation, 2019
The person responsible for arranging the release of this
announcement on behalf of the Company is James McCullough, CEO.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Julian Baines, Non-Executive Chairman
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
(Investment Banking)
Peter Lees (Corporate Broking)
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / James White / George Tzimas (Corporate
Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. In the United States
alone, over 40 million people are classified as having chronic
kidney disease, with nearly 50 percent of individuals with advanced
(Stage IV) disease unaware of the severity of their reduced kidney
function. As a result, many patients progress to kidney failure in
an unplanned manner, ending up having dialysis in the emergency
room without ever seeing a clinical specialist, such as a
nephrologist. Every day 13 patients die in the United States while
waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical diagnostic solutions for kidney disease, one of the most
common and costly chronic medical conditions globally. The
Company's solutions are being designed to make significant
improvements in kidney disease diagnosis and prognosis, clinical
care, patient stratification for drug clinical trials, and drug
target discovery. For more information, visit renalytixai.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKKDNABKDBPB
(END) Dow Jones Newswires
May 21, 2019 02:02 ET (06:02 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024